FINWIRES · TerminalLIVE
FINWIRES

HKG:1672

5 stories mentioning HKG:1672Updated 6d ago

Every FINWIRES story that references HKG:1672, newest first.

Asia

Ascletis Pharma Gets US FDA Nod for Phase III Trial of Obesity Drug Candidate

Ascletis Pharma (HKG:1672) obtained phase III trial clearance for obesity drug ASC30 from the U.S. Food and Drug Administration (FDA), according to a Monday Hong Kong bourse filing.The company expects to announce topline data from the phase III program in the third quarter of 2028, with a U.S. FDA New Drug Application (NDA) filing anticipated by the end of that year.A European Medicines Agency (EMA) Marketing Authorization Application (MAA) filing is also expected in early 2029.

HKG:1672
Asia

Ascletis Pharma's ASC37 Outperforms Tirzepatide in Weight Loss in Mouse Model

Ascletis Pharma's (HKG:1672) ASC37 demonstrated superior weight loss to tirzepatide in a diet-induced obese mouse model, according to a Monday Hong Kong bourse filing.The company will submit an investigational new drug application of both ASC37 once-monthly subcutaneous and oral formulations in the third quarter.Biologics license applications for the formulation will be submitted to the U.S. Food and Drug Administration after phase III completion.

HKG:1672
Asia

Ascletis Pharma Plans Up to HK$300 Million Share Buyback

Ascletis Pharma (HKG:1672) plans to repurchase up to HK$300 million of its shares on the open market under a general mandate approved by shareholders.The shares may be canceled, sold, transferred or held as treasury, as deemed appropriate by the board, according to a Tuesday Hong Kong bourse filing.

HKG:1672
Asia

Ascletis Pharma Gets US FDA Nod for Obesity Drug Trial

Ascletis Pharma (HKG:1672) obtained investigational new drug clearance from the U.S. Food and Drug Administration (FDA) for the phase I study of ASC3, according to a Tuesday Hong Kong bourse filing.The drug is being tested for the treatment of obesity.

HKG:1672
Asia

Ascletis Pharma Completes Patient Enrollment in Phase 2 Study of ASC30

Ascletis Pharma (HKG:1672) said it completed patient enrollment in the phase 2 study of its oral drug ASC30 in the U.S., according to a Hong Kong bourse filing Monday.The firm will study the drug as a treatment for type 2 diabetes over a 13-week period. Topline data from the investigation is expected in the third quarter of 2026, according to Ascletis.ASC30 is also being developed as a treatment for obesity.

HKG:1672

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:1672 in your portfolio
WheelAI
WheelAI
Analyze HKG:1672 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:1672